• 제목/요약/키워드: Potential Risk Assessment of Cardiovascular Disease

검색결과 5건 처리시간 0.053초

Application of Quantitative Assessment of Coronary Atherosclerosis by Coronary Computed Tomographic Angiography

  • Su Nam Lee;Andrew Lin;Damini Dey;Daniel S. Berman;Donghee Han
    • Korean Journal of Radiology
    • /
    • 제25권6호
    • /
    • pp.518-539
    • /
    • 2024
  • Coronary computed tomography angiography (CCTA) has emerged as a pivotal tool for diagnosing and risk-stratifying patients with suspected coronary artery disease (CAD). Recent advancements in image analysis and artificial intelligence (AI) techniques have enabled the comprehensive quantitative analysis of coronary atherosclerosis. Fully quantitative assessments of coronary stenosis and lumen attenuation have improved the accuracy of assessing stenosis severity and predicting hemodynamically significant lesions. In addition to stenosis evaluation, quantitative plaque analysis plays a crucial role in predicting and monitoring CAD progression. Studies have demonstrated that the quantitative assessment of plaque subtypes based on CT attenuation provides a nuanced understanding of plaque characteristics and their association with cardiovascular events. Quantitative analysis of serial CCTA scans offers a unique perspective on the impact of medical therapies on plaque modification. However, challenges such as time-intensive analyses and variability in software platforms still need to be addressed for broader clinical implementation. The paradigm of CCTA has shifted towards comprehensive quantitative plaque analysis facilitated by technological advancements. As these methods continue to evolve, their integration into routine clinical practice has the potential to enhance risk assessment and guide individualized patient management. This article reviews the evolving landscape of quantitative plaque analysis in CCTA and explores its applications and limitations.

낮은 칼슘 수치에서 심혈관질환의 잠재 위험도 평가 (Potential Risk Assessment of Cardiovascular Disease in Low Calcium-Score)

  • 유행수;박지군;정봉재;노시철;최일홍;정형진;강상식
    • 한국방사선학회논문지
    • /
    • 제7권6호
    • /
    • pp.369-376
    • /
    • 2013
  • 심혈관 질환의 위험도를 조기에 발견해 예방하기 위한 다양한 시도들이 이루어지고 있는 데 질환자를 대상으로 한 많은 연구를 통해 관상동맥 석회화의 판정기준이 마련되었으나 수치가 100 이상이 되어야 진행의 흐름을 예상할 수 있었다. 이에 본 연구는 자각증상이 없는 일반인을 대상으로 칼슘 수치와 체성분 분석, 혈중지질 수치의 상관관계를 수치화하여 기존 연구와 비교분석하여 칼슘 수치가 낮을 때에도 잠재적인 심혈관 질환의 위험성을 나타낼 수 있을지에 대한 평가를 해 보았다. 연구 결과 체성분 분석에서 칼슘수치가 0-10일 때 와 칼슘수치가 11-100일 때 유의한 상관관계가 있는 BMI와 WHR을 살펴보면 정상범위의 빈도수가 많아 평균값이 정상범위에 머물렀으나 21%의 상대적인 위험률이 도출되었으며 지질검사에서도 유의한 상관관계가 있는 HDL과 TG를 살펴보면 정상범위의 빈도수가 많아 평균값이 정상범위에 머물렀으나 21-40%의 상대적인 위험률이 도출되었다. 또한 상관관계가 없는 BFM과 BMR에서는 표준이상에서 빈도수가 높아 평균값도 높게 나타났으며 상대적 위험도가 31-93%로 도출되었으며 지질검사에서 상관관계가 없는 TC가 200 mg/dl이상으로 죽상동맥경화증의 발생이 급격히 증가하여 LDL값이 높게 나타났으며 죽상경화증의 발생을 억제하기 위해 이미 생긴 죽종에서 콜레스테롤을 제거하는 작용을 하는 HDL의 값도 동시에 증가한 것으로 보인다. 이 때의 상대적 위험률은 43-50%로 도출되었다. 즉 칼슘 수치가 낮을 때에도 심혈관 질환의 발생률이 내재되어 있음을 알 수 있었다.

소화기 암환자 호흡곤란의 정확한 평가와 치료 (Accurate Evaluation and Treatment of Dyspnea in Patients with Gastrointestinal Cancer)

  • 이종윤
    • Journal of Digestive Cancer Research
    • /
    • 제11권2호
    • /
    • pp.108-113
    • /
    • 2023
  • Dyspnea is a common symptom among patients with gastrointestinal cancer, and a comprehensive evaluation of their respiratory function is essential. Self-reporting aids in the assessment of the degree of dyspnea, while objective examination methods are performed to identify the potential underlying causes when subjective symptoms are present. Standard treatment protocols should be followed for potentially reversible and common causes of dyspnea, such as pleural effusion, pneumonia, airway obstruction, anemia, asthma, exacerbation of chronic obstructive pulmonary disease, pulmonary thromboembolism, or drug-induced interstitial lung disease. Careful and close monitoring is required due to the high frequency of pulmonary thromboembolism and the risk of cardiovascular accidents, drug-induced interstitial lung disease, or other complications from some anticancer drugs. In case of hypoxemia with an oxygen saturation of 90% or less, palliative treatment should comprise standard oxygen therapy such as nasal cannula, mask, or high-flow nasal cannula. If non-pharmacological oxygen therapy is not effective, pain control through systemic narcotic analgesics and anti-anxiety therapy with benzodiazepines may be helpful.

Intelligent System for the Prediction of Heart Diseases Using Machine Learning Algorithms with Anew Mixed Feature Creation (MFC) technique

  • Rawia Elarabi;Abdelrahman Elsharif Karrar;Murtada El-mukashfi El-taher
    • International Journal of Computer Science & Network Security
    • /
    • 제23권5호
    • /
    • pp.148-162
    • /
    • 2023
  • Classification systems can significantly assist the medical sector by allowing for the precise and quick diagnosis of diseases. As a result, both doctors and patients will save time. A possible way for identifying risk variables is to use machine learning algorithms. Non-surgical technologies, such as machine learning, are trustworthy and effective in categorizing healthy and heart-disease patients, and they save time and effort. The goal of this study is to create a medical intelligent decision support system based on machine learning for the diagnosis of heart disease. We have used a mixed feature creation (MFC) technique to generate new features from the UCI Cleveland Cardiology dataset. We select the most suitable features by using Least Absolute Shrinkage and Selection Operator (LASSO), Recursive Feature Elimination with Random Forest feature selection (RFE-RF) and the best features of both LASSO RFE-RF (BLR) techniques. Cross-validated and grid-search methods are used to optimize the parameters of the estimator used in applying these algorithms. and classifier performance assessment metrics including classification accuracy, specificity, sensitivity, precision, and F1-Score, of each classification model, along with execution time and RMSE the results are presented independently for comparison. Our proposed work finds the best potential outcome across all available prediction models and improves the system's performance, allowing physicians to diagnose heart patients more accurately.

Effect of coadministration of enriched Korean Red Ginseng (Panax ginseng) and American ginseng (Panax quinquefolius L) on cardiometabolic outcomes in type-2 diabetes: A randomized controlled trial

  • Jovanovski, Elena;Smircic-Duvnjak, Lea;Komishon, Allison;Au-Yeung, Fei (Rodney);Sievenpiper, John L.;Zurbau, Andreea;Jenkins, Alexandra L.;Sung, Mi-Kyung;Josse, Robert;Li, Dandan;Vuksan, Vladimir
    • Journal of Ginseng Research
    • /
    • 제45권5호
    • /
    • pp.546-554
    • /
    • 2021
  • Background: Diabetes mellitus and hypertension often occur together, amplifying cardiovascular disease (CVD) risk and emphasizing the need for a multitargeted treatment approach. American ginseng (AG) and Korean Red Ginseng (KRG) species could improve glycemic control via complementary mechanisms. Additionally, a KRG-inherent component, ginsenoside Rg3, may moderate blood pressure (BP). Our objective was to investigate the therapeutic potential of coadministration of Rg3-enriched Korean Red Ginseng (Rg3-KRG) and AG, added to standard of care therapy, in the management of hypertension and cardiometabolic risk factors in type-2 diabetes. Methods: Within a randomized controlled, parallel design of 80 participants with type-2 diabetes (HbA1c: 6.5-8%) and hypertension (systolic BP: 140-160 mmHg or treated), supplementation with either 2.25 g/day of combined Rg3-KRG + AG or wheat-bran control was assessed over a 12-wk intervention period. The primary endpoint was ambulatory 24-h systolic BP. Additional endpoints included further hemodynamic assessment, glycemic control, plasma lipids and safety monitoring. Results: Combined ginseng intervention generated a mean ± SE decrease in primary endpoint of 24-h systolic BP (-3.98 ± 2.0 mmHg, p = 0.04). Additionally, there was a greater reduction in HbA1c (-0.35 ± 0.1% [-3.8 ± 1.1 mmol/mol], p = 0.02), and change in blood lipids: total cholesterol (-0.50 ± 0.2 mmol/l, p = 0.01), non-HDL-C (-0.54 ± 0.2 mmol/l, p = 0.01), triglycerides (-0.40 ± 0.2 mmol/l, p = 0.02) and LDL-C (-0.35 ± 0.2 mmol/l, p = 0.06) at 12 wks, relative to control. No adverse safety outcomes were observed. Conclusion: Coadministration of Rg3-KRG + AG is an effective addon for improving BP along with attaining favorable cardiometabolic outcomes in individuals with type 2 diabetes. Ginseng derivatives may offer clinical utility when included in the polypharmacy and lifestyle treatment of diabetes. Clinical trial registration: Clinicaltrials.gov identifier, NCT01578837;